

Clinical Trial Protocol

Iranian Registry of Clinical Trials

18 Sep 2026

Pharmacokinetic assessments of Escitalopram tablet with brand drugs (Cipralext 20mg Loundbeck A/S Denmark).

Protocol summary

Study aim

In- Vivo Bioequivalence study of Escitalopram tablet 20mg ABIDI (Ezipam 20mg) with brand drugs (Cipralext 20mg Loundbeck A/S Denmark).

Design

Single dose of Escitalopram 20 mg Abidi Pharmaceutical Company.

Settings and conduct

This study will be conducted in two-way, cross-over and fasting, and on two sets of healthy volunteers. The study will be conducted in two periods of twenty-four hours. The interval between these two periods, which is called the wash-out time, is determined by the half-life of the drug plasma, which according to scientific sources should be at least 5 to 7 half-life of the drug in the case of the drug under study. The plan will take a week to clean up the drug, given the biological half-life of the drugs in the drug form. In the first round, candidates are divided into two groups, and the first group receives a test tablet and the second group receives a similar tablet. Blood samples will be taken by the volunteer by the technician immediately after taking the drug, and the preparation steps of the samples, including plasma separation and drug extraction, are performed to analyze the amount of drug.

Participants/Inclusion and exclusion criteria

24 participants will be selected from non-smoking, non-pregnant people without history of heart, kidney and liver disease from both sex (male & female). The ages and BMIs of participant should be in the range of 18-55 and 18-28 respectively.

Intervention groups

Intervention group Single dose Escitalopram tablet 20mg Abidi Pharmaceutical Company and Control group Single dose of Cipralext tablet with brand drugs 20mg Loundbeck A/S.

Main outcome variables

Determination of blood drug concentration.

General information

Reason for update

Acronym

IRCT registration information

IRCT registration number: **IRCT20200105046010N14**

Registration date: **2020-11-02, 1399/08/12**

Registration timing: **prospective**

Last update: **2020-11-02, 1399/08/12**

Update count: **0**

Registration date

2020-11-02, 1399/08/12

Registrant information

Name

Javad Shokri

Name of organization / entity

Country

Iran (Islamic Republic of)

Phone

+98 41 3661 4125

Email address

shokri.j@gmail.com

Recruitment status

Recruitment complete

Funding source

Expected recruitment start date

2020-12-24, 1399/10/04

Expected recruitment end date

2021-08-26, 1400/06/04

Actual recruitment start date

empty

Actual recruitment end date

empty

Trial completion date

empty

Scientific title

Pharmacokinetic assessments of Escitalopram tablet with brand drugs (Ciprallex 20mg Loundbeck A/S Denmark).

Public title

In-vivo Bioequivalence Test of Escitalopram tablet with brand drug Ciprallex Made by Loundbeck A/S Denmark.

Purpose

Treatment

Inclusion/Exclusion criteria

Inclusion criteria:

General health (liver, heart, kidney) Body mass index(18-28) Informed consent Age(18-60)

Exclusion criteria:

Smoking Pregnancy Alcohol & Drug addiction

Age

From **18 years** old to **60 years** old

Gender

Male

Phase

Bioequivalence

Groups that have been masked

- Participant

Sample size

Target sample size: **24**

Randomization (investigator's opinion)

Randomized

Randomization description

Random allocation law is the simplest method of finite randomization. This method represents a large block for the entire sample size. This means that a balance in the number of people assigned to each group will be achieved at the end of the study. For this purpose, first determine a total sample size (24 people), then write the names of the people on paper, and after folding in aluminum foil, pour it into a glass, and then randomly remove the papers and open the first 12 people in group A and The rest are selected as group B.

Blinding (investigator's opinion)

Single blinded

Blinding description

Candidates are not aware of the test drug or brand name. In a one-blind study, information that could distort the test result is hidden from the candidates, but the person in charge of the test is aware of it. Escitalopram and Escitalopram ® are removed from their packaging by the executor and placed in similar and coded cans. Volunteers will not be informed about receiving the brand or test dosage form.

Placebo

Not used

Assignment

Crossover

Other design features

Secondary Ids

empty

Ethics committees

1

Ethics committee

Name of ethics committee

Tabriz University of Medical Sciences Ethics Committee

Street address

Third floor, Central Bulding of Tabriz University of Medical Sciences, Daneshgah St.

City

Tabriz

Province

East Azarbaijan

Postal code

5166614766

Approval date

2019-11-25, 1398/09/04

Ethics committee reference number

IR.TBZMED.REC.1398.912

Health conditions studied

1

Description of health condition studied

In this study, the disease is not examined. Subject bioequivalence test and reference tablets Escitalopram studied.

ICD-10 code

ICD-10 code description

Primary outcomes

1

Description

Determination of blood drug concentration.

Timepoint

Sampling times in this study will be 0, 1, 2, 2:30, 3, 3:20, 3:40, 4, 4:20, 4: 40, 5, 6, 8, 10, 12, 24, 48, 72 hours.

Method of measurement

Liquid Chromatography with tandem mass spectroscopy detector

Secondary outcomes

empty

Intervention groups

1

Description

Intervention group: Single dose Escitalopram tablet 20mg Abidi Pharmaceutical Company.

Category

Treatment - Drugs

2

Description

Control group: Single dose of Ciprallex tablet with brand

drugs 20mg Loundbeck A/S Denmark
Category
Treatment - Drugs

Recruitment centers

1

Recruitment center

Name of recruitment center
Simin Baspar Teyf Gostar Company
Full name of responsible person
Javad Shokri
Street address
No.48, Ferdos Street
City
Tabriz
Province
East Azarbaijan
Postal code
5167874434
Phone
+98 41 3384 2724
Email
Shokri.j@gmail.com

Sponsors / Funding sources

1

Sponsor

Name of organization / entity
Abidi Pharmaceutical Company
Full name of responsible person
Amir Razavian
Street address
No. 72, Obaidi Boulevard, Karaj special road, 8 km of
Shahid Lashkari highway
City
Tehran
Province
Tehran
Postal code
1389776363
Phone
+98 21 4452 2451
Email
info@abidi-diabetes.com
Grant name
Grant code / Reference number
**Is the source of funding the same sponsor
organization/entity?**
No
Title of funding source
Abidi Pharmaceutical Company
Proportion provided by this source
100
Public or private sector
Private
Domestic or foreign origin
Domestic
Category of foreign source of funding

empty

Country of origin
Type of organization providing the funding
Other

Person responsible for general inquiries

Contact

Name of organization / entity
Tabriz University of Medical Sciences
Full name of responsible person
Javad Shokri
Position
Professor
Latest degree
Ph.D.
Other areas of specialty/work
Medical Pharmacy
Street address
Faculty of Pharmacy, University of Medical Sciences,
Daneshgah Street,Tabriz East Azerbaijan
City
Tabriz
Province
East Azarbaijan
Postal code
5166414766
Phone
+98 41 3334 8489
Email
Shokri.j@gmail.com

Person responsible for scientific inquiries

Contact

Name of organization / entity
Tabriz University of Medical Sciences
Full name of responsible person
Javad Shokri
Position
Professor
Latest degree
Ph.D.
Other areas of specialty/work
Medical Pharmacy
Street address
آدرس خیابان Faculty of Pharmacy, University of Medical
Sciences, Daneshgah Street,Tabriz East Azerbaijan
City
Tabriz
Province
East Azarbaijan
Postal code
5166414766
Phone
+98 41 3334 8489
Email
Shokri.j@gmail.com

Person responsible for updating data

Contact

Name of organization / entity

Tabriz University of Medical Sciences

Full name of responsible person

Javad Shokri

Position

Professor

Latest degree

Ph.D.

Other areas of specialty/work

Medical Pharmacy

Street address

Faculty of Pharmacy, University of Medical Sciences,
Daneshgah Street, Tabriz East Azerbaijan

City

Tabriz

Province

East Azarbaijan

Postal code

5166414766

Phone

+98 41 3334 8489

Email

Shokri.j@gmail.com

Sharing plan

Deidentified Individual Participant Data Set (IPD)

No - There is not a plan to make this available

Justification/reason for indecision/not sharing IPD

These data are as secure between researcher and related industries.

Study Protocol

No - There is not a plan to make this available

Statistical Analysis Plan

No - There is not a plan to make this available

Informed Consent Form

No - There is not a plan to make this available

Clinical Study Report

No - There is not a plan to make this available

Analytic Code

No - There is not a plan to make this available

Data Dictionary

Yes - There is a plan to make this available

Title and more details about the data/document

Only protocol and methods of study are sharable.

When the data will become available and for how long

After finishing of the protocol (Probably 6 months receiving IRCT code)

To whom data/document is available

Pharmaceutical and medical sciences researchers.

Under which criteria data/document could be used

Projects information's for any publications is not allowed.

From where data/document is obtainable

Contact with E-mail of the main researcher.

What processes are involved for a request to access data/document

Personal and academic details and the aim of the request.

Comments